Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004032 | Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00016289 | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | completed | Phase 1 / Phase 2 | 138 | AbbVie (prior sponsor, Abbott)INDUSTRY | 9 | Jan 18, 2013 | clinicaltrials |
| NCT00003358 | Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00335998 | Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00050414 | A Study of Trabectedin in Patients With Advanced Ovarian Cancer | completed | Phase 2 | 147 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jan 10, 2013 | clinicaltrials |
| NCT00396591 | AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | completed | Phase 2 | 16 | SanofiINDUSTRY | 3 | Jan 10, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT00327444 | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | completed | Phase 2 / Phase 3 | 58 | SanofiINDUSTRY | 9 | Jan 1, 2013 | clinicaltrials |
| NCT00672295 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | completed | Phase 1 | 11 | AA SecordOTHER | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00837993 | Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System | completed | — | 241 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00610714 | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer(OVERT-1) | completed | Phase 2 | 211 | AstraZenecaINDUSTRY | 12 | Dec 18, 2012 | clinicaltrials |
| NCT00181688 | Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Dec 5, 2012 | clinicaltrials |
| NCT00316173 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | completed | Phase 2 | 77 | GlaxoSmithKlineINDUSTRY | 2 | Nov 27, 2012 | clinicaltrials |
| NCT00002671 | Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00005051 | Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00900406 | Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant | completed | — | 190 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 6, 2012 | clinicaltrials |
| NCT00861120 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type(PaLiDo) | completed | Phase 2 | 33 | Vejle HospitalOTHER | 4 | Oct 26, 2012 | clinicaltrials |
| NCT00078845 | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2012 | clinicaltrials |
| NCT00069160 | Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2012 | clinicaltrials |
| NCT01012336 | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin | completed | Phase 2 | 89 | Samsung Medical CenterOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00433407 | T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors | completed | N/A | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT00563836 | Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | completed | Phase 2 | 41 | Neovii BiotechINDUSTRY | 2 | Oct 3, 2012 | clinicaltrials |
| NCT00003939 | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 132 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Sep 24, 2012 | clinicaltrials |
| NCT00006230 | Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 24, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00003072 | Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | 80 | University of California, San FranciscoOTHER | 1 | Sep 21, 2012 | clinicaltrials |
| NCT01041235 | Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies | completed | Phase 1 | 29 | Azaya Therapeutics, Inc.INDUSTRY | 1 | Sep 6, 2012 | clinicaltrials |
| NCT00003772 | Quality-of-Life Assessment in Patients With Ovarian Cancer | completed | — | 372 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Aug 27, 2012 | clinicaltrials |
| NCT00296816 | TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary(TEACO) | completed | Phase 2 | 132 | SanofiINDUSTRY | 1 | Aug 23, 2012 | clinicaltrials |
| NCT00452985 | Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer(OCSTUD) | completed | — | 30 | SanofiINDUSTRY | 1 | Aug 14, 2012 | clinicaltrials |
| NCT00004081 | Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 30 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 13, 2012 | clinicaltrials |
| NCT00165152 | Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing | completed | N/A | 150 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00501644 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00486707 | Ovarian Cancer Patient Questionnaire on Genetic Testing | completed | — | 237 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00377429 | Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | completed | Phase 2 | 47 | Neovii BiotechINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00002764 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | completed | Phase 3 | 340 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00002903 | Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer | completed | Phase 2 | 25 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Jul 2, 2012 | clinicaltrials |
| NCT00281515 | Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Jun 29, 2012 | clinicaltrials |
| NCT00877253 | Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer | completed | Phase 1 | 18 | Samyang Biopharmaceuticals CorporationINDUSTRY | 0 | Jun 12, 2012 | clinicaltrials |
| NCT00003670 | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00004166 | Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy | completed | Phase 3 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00004895 | Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | completed | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00102973 | TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer | completed | Phase 3 | 244 | TelikINDUSTRY | 1 | May 31, 2012 | clinicaltrials |
| NCT00130520 | Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer | completed | Phase 2 | 40 | University of ArizonaOTHER | 1 | May 28, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2013source: clinicaltrials